全球脊柱关节炎生物制剂改善病情抗风湿药处方的不公平性:ASAS-COMOSPA研究结果
基于22国3370例符合ASAS脊柱关节炎标准的横断面研究,分析生物制剂使用与国家社会经济因素的关系。调整人口学和临床变量后,各国生物制剂使用率仍存在重要差异(P<0.001),粗率从中国5%到比利时74%。较高卫生支出与较高生物制剂使用相关但未达统计学显著(OR 1.96;95%CI 0.94至4.10)。
要点
- 22国3370例脊柱关节炎患者中,1275例(38%)使用生物制剂,粗率从中国5%到比利时74%。
- 调整相关人口学和临床变量后,各国生物制剂使用仍存在重要差异(P<0.001)。
- 较高卫生支出与较高生物制剂使用相关但未达统计学显著(OR 1.96;95%CI 0.94至4.10)。
核心结论
- 在专科脊柱关节炎中心随访的患者中,各国生物制剂使用率仍存在重要残余差异,且独立于临床和国家层面社会经济因素等已知因素。
研究设计与样本
- 多国横断面ASAS脊柱关节炎共病研究,纳入符合ASAS脊柱关节炎标准的患者,采用多水平logistic回归分析并考虑国家层面。
主要发现
- 共纳入22国3370例患者(平均年龄43岁,标准差14;男性66%;中轴病88%)。
- 1275例(38%)患者使用生物制剂,粗率从中国5%到比利时74%。
- 调整相关人口学和临床变量后,各国生物制剂使用仍存在重要差异(P<0.001)。
- 较高卫生支出与较高生物制剂使用相关但未达统计学显著(OR 1.96;95%CI 0.94至4.10)。
- 较高卫生支出国家的传统合成改善病情抗风湿药使用显著较低(OR 0.32;95%CI 0.15至0.65)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The value of biological disease-modifying antirheumatic drugs (bDMARDs) in spondyloarthritis (SpA) is well recognised, but global access to these treatments can be limited due to high costs and other factors. This study explores country variation in the use of bDMARDs in SpA in relation to country-level socioeconomic factors. METHODS: Patients fulfilling the Assessment in SpondyloArthritis International Society (ASAS) SpA criteria in the multinational, cross-sectional ASAS Comorbidities in Spondyloarthritis study were studied. Current use of bDMARDs or conventional synthetic DMARDs (csDMARDs) was investigated in separate models, with multilevel logistic regression analysis, taking the country level into account. Contribution of socioeconomic factors, including country health expenditures, gross domestic product and human development index as independent country-level factors, was explored individually, in models adjusted for sociodemographic as well as clinical variables. RESULTS: In total, 3370 patients from 22 countries were included (mean (SD) age 43 (14) years; 66% male; 88% axial disease). Across countries, 1275 (38%) patients were bDMARD users. Crude mean bDMARD use varied between 5% (China) to 74% (Belgium). After adjustment for relevant sociodemographic and clinical variables, important variation in bDMARD use across countries remained (P<0.001). Country-level socioeconomic factors, specifically higher health expenditures, were related to higher bDMARD uptake, though not meeting statistical significance (OR 1.96; 95% CI 0.94 to 4.10). csDMARD uptake was significantly lower in countries with higher health expenditures (OR 0.32; 95% CI 0.15 to 0.65). Similar trends were seen with the other socioeconomic variables. CONCLUSIONS: There remains important residual variation across countries in bDMARD uptake of patients with SpA followed in specialised SpA centres. This is independent of well-known factors for bDMARD use such as clinical and country-level socioeconomic factors.
引用
- Nikiphorou E, van der Heijde D, Norton S, et al. Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. Ann Rheum Dis. 2017. PMID: 29222349. doi:10.1136/annrheumdis-2017-212457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。